Rview study of Covid 19 virus rapid detection systems and their technological classification

Bagheri, Zeinab; Mirzapour, Aboulfazl

Rview study of Covid 19 virus rapid detection systems and their technological classification

Document Type : Analytic Review

Authors

Zeinab Bagheri ¹

Aboulfazl Mirzapour ²

¹ shahid beheshti university

² Tarbiat miodares university

Abstract

Rapid test methods are laboratory instruments that can be used in the point of care and for suspicious cases. In an ideal rapid detection method, the steps for preparing a sample to obtain an analytical result should be as short as possible, and unskilled operators should be able to execute it and understand the result. To accomplish such a process, it is better to perform all the steps including sample preparation, detection procedure and acquisition of an intelligible signal in one device. These assay systems can include microfluidic chips, paper-based sensors, or even single-tube reactions. Corona Pandemic offers many products for the rapid detection of the Covid 19 virus, which diffrent products were commercially developed. Due to the sensitivity of the diagnosis at different stages of the disease, only a small number of technologies could be applied in practice. In this review article, these products are categorized and reviewed based on technological properties. Also, these technologies have been compared in terms of important components such as sensitivity, accuracy, cost and speed of the process in the diagnosis and management and control of COVID-19 pandemic. Also the application of each technology is explained. Finally, the best technology that can play a major role is introduced.

Keywords

Rapid detection

Covid 19 virus

technological classification

20.1001.1.23222115.1400.13.1.9.8

Subjects

Nanotechnology

[1] B. Hu, “Characteristics of SARS-CoV-2 and COVID-19,” Nat. Rev. Microbiol., no. December, 2019, doi: 10.1038/s41579-020-00459-7.
[2] T. Wang et al., “Comorbidities and multi-organ injuries in the treatment of COVID-19,” Lancet, vol. 395, no. 10228, p. e52, 2020, doi: 10.1016/S0140-6736(20)30558-4.
[3] C. Menni et al., “Real-time tracking of self-reported symptoms to predict potential COVID-19,” Nat. Med., vol. 26, no. July, 2020, doi: 10.1038/s41591-020-0916-2.
[4] B. Udugama et al., “Diagnosing COVID-19 : The Disease and Tools for Detection,” ACS Nano, vol. 14, pp. 3822–3855, 2020, doi: 10.1021/acsnano.0c02624.
[5] N. Ravi, D. L. Cortade, E. Ng, and S. X. Wang, “Diagnostics for SARS-CoV-2 detection : A comprehensive review of the FDA-EUA COVID-19 testing landscape,” Biosens. Bioelectron., vol. 165, no. April, p. 112454, 2020, doi: 10.1016/j.bios.2020.112454.
[6] Z. Qin, R. Peng, I. K. Baravik, and X. Liu, “Fighting COVID-19 : Integrated Micro- and Nanosystems for Viral Infection Diagnostics,” Matter, vol. 3, no. 3, pp. 628–651, 2020, doi: 10.1016/j.matt.2020.06.015.
[7] B. Giri, S. Pandey, R. Shrestha, K. Pokharel, F. S. Ligler, and B. B. Neupane, “Review of analytical performance of COVID-19 detection methods,” Anal. Bioanal. Chem., vol. 413, pp. 35–48, 2021.
[8] “Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices.” https://www.fda.gov/medical-devices/emergency-use-authorizations-medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices.
[9] “COVID-19 Diagnostics & testing,” [Online]. Available: https://www.finddx.org/covid-19/.
[10] “RADx Programs,” [Online]. Available: https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs.
[11] C. This et al., “Assay Techniques and Test Development for COVID-19 Diagnosis,” ACS Cent. Sci., 2020, doi: 10.1021/acscentsci.0c00501.
[12] I. K. Rai, Praveen,Ballamoole Krishna Kumar, Vijaya Kumar Deekshit, Indrani Karunasagar, “Detection technologies and recent developments in the diagnosis of COVID-19 infection,” Appl. Microbiol. Biotechnol., 2021, doi: 10.1007/s00253-020-11061-5.
[13] W. Feng et al., “Molecular Diagnosis of COVID-19: Challenges and Research Needs,” Anal. Chem., 2020, doi: 10.1021/acs.analchem.0c02060.
[14] Zhu, Hanliang, H. Zhang, S. Ni, M. Korabečná, L. Yobas, and P. Neuzil, “The vision of point-of-care PCR tests for the COVID-19 pandemic and beyond,” Trends Anal. Chem., vol. 130, pp. 1–13, 2020, doi: 10.1016/j.trac.2020.115984.
[15] M. Allam, S. Cai, S. Ganesh, M. Venkatesan, C.-S. Group, and A. F. Coskun, “COVID-19 Diagnostics, Tools, and Prevention,” Diagnostics, vol. 10, no. 6, pp. 1–33, 2020, doi: 10.3390/diagnostics10060409.
[16] B. H. Foy, J. C. T. Carlson, E. Reinertsen, R. P. I. Valls, R. P. Lopez, and E. Palanques-tost, “Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection,” JAMA Netw. Open, vol. 3, no. 9, pp. 1–13, 2020, doi: 10.1001/jamanetworkopen.2020.22058.
[17] L. Xu, D. Li, S. Ramadan, Y. Li, and N. Klein, “Biosensors and Bioelectronics Facile biosensors for rapid detection of COVID-19,” Biosens. Bioelectron., vol. 170, no. August, p. 112673, 2020, doi: 10.1016/j.bios.2020.112673.
[18] “Instrument-free PCR,” [Online]. Available: https://www.visbymedical.com/covid-19-test/.
[19] L. Zhou et al., “Programmable low-cost DNA-based platform for viral RNA detection,” Sci. Adv. |, no. September, pp. 1–10, 2020.
[20] M. F. Wolthuis, J. C. T. Eijkel, and L. I. Segerink, “Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities,” Biosens. Bioelectron., p. 112445, 2020, doi: 10.1016/j.bios.2020.112445.
[21] “A CRISPR-based detection solution for SARS-CoV-2,” [Online]. Available: https://mammoth.bio/covid/.
[22] Q. Chen, Z. He, F. Mao, H. Pei, H. Cao, and X. Liu, “Diagnostic technologies for COVID-19 : a review,” RSC Adv., vol. 10, p. 35257, 2020, doi: 10.1039/d0ra06445a.
[23] “Covid Antibody and Antigen Test Kits.” https://hardydiagnostics.com/coronavirus-covid-19-update/.
[24] P. Pokhrel, C. Hu, and H. Mao, “Detecting the Coronavirus ( COVID-19 ),” ACS Sensors, vol. 5, no. 8, pp. 2283–2296, 2020, doi: 10.1021/acssensors.0c01153.
[25] P. R. W. Peeling, P. P. L. Olliaro, D. I. Boeras, and N. Fongwen, “Personal View Scaling up COVID-19 rapid antigen tests : promises and challenges,” Lancet Infect. Dis., vol. 3099, no. 21, pp. 21–26, 2021, doi: 10.1016/S1473-3099(21)00048-7.
[26] “Clip COVID Rapid Antigen Test,” [Online]. Available: https://cliphealth.com/.
[27] “Access IL-6 Assay.” https://www.beckmancoulter.com/products/immunoassay/access-il-6-assay.
[28] “Elecsys® IL-6 Early marker in acute inflammation.” https://diagnostics.roche.com/global/en/products/params/elecsys-il-6.html.
[29] R. Weissleder, H. Lee, J. Ko, and M. J. Pittet, “COVID-19 diagnostics in context,” Sci. Transl. Med. |, vol. 2019, pp. 1–7, 2020.
[30] V. Bhavana, P. Thakor, S. B. Singh, and N. K. Mehra, “COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic,” Life Sci., p. 118336, 2020, doi: 10.1016/j.lfs.2020.118336.
[31] V. Haldane et al., “Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries,” Nat. Med., pp. 1–7, 2021, doi: 10.1038/s41591-021-01381-y.
[32] L. Falzone, G. Gattuso, A. Tsatsakis, D. A. Spandidos, and M. Libra, “Current and innovative methods for the diagnosis of COVID ‑ 19 infection ( Review ),” Int. J. Mol. Med., vol. 47, pp. 1–23, 2021, doi: 10.3892/ijmm.2021.4933.
[33] J. D. Whitman et al., “Evaluation of SARS-CoV-2 serology assays reveals a range of test performance,” Nat. Biotechnol., vol. 38, no. October, pp. 1174–1183, 2020, doi: 10.1038/s41587-020-0659-0.